SMAD2 and hepatocellular carcinoma: Glabridin suppressed cancer stem-cell-like features in hepatocellular carcinoma cells by the upregulation of miR-148a that targets SMAD2 (mothers against decapentaplegic homolog 2) associated with the inhibition of TGF (transforming growth factor)-β/SMAD2 signaling [337,338].